{
    "clinical_study": {
        "@rank": "6735", 
        "arm_group": {
            "arm_group_label": "Treatment (MLN0128, bevacizumab)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive MLN0128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of MLN0128 when given in\n      combination with bevacizumab in treating patients with glioblastoma, a type of brain tumor,\n      or a solid tumor that has spread and not responded to standard treatment. MLN0128 may stop\n      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal\n      antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and\n      spread. Bevacizumab may also stop the progression of tumors by blocking the growth of new\n      blood vessels necessary for tumor growth."
        }, 
        "brief_title": "MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors", 
        "condition": [
            "Adult Giant Cell Glioblastoma", 
            "Adult Glioblastoma", 
            "Adult Gliosarcoma", 
            "Endometrial Clear Cell Carcinoma", 
            "Endometrial Papillary Serous Carcinoma", 
            "Ovarian Clear Cell Cystadenocarcinoma", 
            "Ovarian Endometrioid Adenocarcinoma", 
            "Ovarian Mucinous Cystadenocarcinoma", 
            "Ovarian Serous Cystadenocarcinoma", 
            "Recurrent Adult Brain Tumor", 
            "Recurrent Endometrial Carcinoma", 
            "Recurrent Fallopian Tube Cancer", 
            "Recurrent Ovarian Epithelial Cancer", 
            "Recurrent Primary Peritoneal Cavity Cancer", 
            "Stage IIIA Fallopian Tube Cancer", 
            "Stage IIIA Ovarian Epithelial Cancer", 
            "Stage IIIA Primary Peritoneal Cavity Cancer", 
            "Stage IIIB Fallopian Tube Cancer", 
            "Stage IIIB Ovarian Epithelial Cancer", 
            "Stage IIIB Primary Peritoneal Cavity Cancer", 
            "Stage IIIC Fallopian Tube Cancer", 
            "Stage IIIC Ovarian Epithelial Cancer", 
            "Stage IIIC Primary Peritoneal Cavity Cancer", 
            "Stage IV Fallopian Tube Cancer", 
            "Stage IV Ovarian Epithelial Cancer", 
            "Stage IV Primary Peritoneal Cavity Cancer", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Brain Neoplasms", 
                "Carcinoma", 
                "Cystadenocarcinoma", 
                "Glioblastoma", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Adenocarcinoma, Clear Cell", 
                "Adenomyoepithelioma", 
                "Carcinoma, Endometrioid", 
                "Cystadenocarcinoma, Mucinous", 
                "Cystadenocarcinoma, Serous", 
                "Gliosarcoma", 
                "Neoplasms, Glandular and Epithelial", 
                "Ovarian Neoplasms", 
                "Neoplasms", 
                "Endometrial Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily\n      oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with\n      advanced solid tumors including recurrent glioblastoma (GBM).\n\n      II. To evaluate the overall safety and tolerability of the combination of MLN0128 and\n      bevacizumab.\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess the preliminary anti-tumor activity of the combination of MLN0128 and\n      bevacizumab, as determined by response rate (RR), progression-free survival (PFS) and\n      overall survival (OS).\n\n      II. To assess tolerability throughout study therapy with MLN0128 and bevacizumab, including\n      beyond the MTD interval with the following measures of cumulative treatment-related\n      toxicities: frequency of toxicities leading to missed doses or delays; percentage of cycles\n      given or not within 7 days of their scheduled times; percentage of actual planned dosage\n      administration; percentage of patients that discontinue study drugs due to treatment related\n      toxicity.\n\n      TERTIARY OBJECTIVES:\n\n      I. To assess cerebrospinal fluid (CSF) penetration of MLN0128 in combination with\n      bevacizumab in patients with recurrent GBM by evaluating the plasma and CSF concentrations\n      of MLN0128 in the absence and presence of bevacizumab.\n\n      II. To perform archival tumor analysis for markers of dysregulated cell signaling that may\n      predict response to mechanistic target of rapamycin (mTOR) inhibitor therapy such as\n      epidermal growth factor receptor (EGFR) (expression by immunohistochemistry [IHC] and\n      amplification by fluorescent in situ hybridization [FISH]), phosphatase and tensin homolog\n      (PTEN) (expression by IHC and deletion by FISH), phosphorylated (p)-protein kinase B (AKT),\n      p-ribosomal protein S6 kinase (S6K), p-eukaryotic translation initiation factor 4E binding\n      protein 1 (4EBP), p-mTOR and p-mitogen-activated protein kinase 1 (Erk) in patients with\n      recurrent GBM.\n\n      III. To analyze select phosphorylated proteins (ERK, AKT, mTOR, 4EBP1, glycogen synthase\n      kinase 3-beta [GSK3beta], ribosomal protein S6 kinase, 70kDa, polypeptide 2 [p70S6K], rS6)\n      from tumor biopsies obtained at baseline and after treatment with MLN0128 from endometrial\n      and ovarian cancer patients enrolled in stage 2.\n\n      IV. To analyze circulating plasma levels of angiogenic growth factors before, during and\n      after treatment with MLN0128 and bevacizumab V. To perform genetic mutation analysis and\n      proteomic analysis of tissue from biopsies of endometrial and ovarian cancer patients\n      including analysis of Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine\n      sarcoma viral oncogene homolog B (BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase,\n      catalytic subunit alpha (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1) and\n      PTEN.\n\n      OUTLINE: This is a dose-escalation study of MLN0128.\n\n      Patients receive MLN0128 orally (PO) once daily (QD) and bevacizumab intravenously (IV) over\n      30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease\n      progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 30 days and then annually\n      thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have a histologically/cytologically confirmed diagnosis of recurrent\n             glioblastoma or an advanced solid tumor in which bevacizumab has shown benefit in\n             specific disease population and for which standard or curative measures do not exist\n             or are no longer effective\n\n          -  Measurable or evaluable disease as assessed by Response Evaluation Criteria in Solid\n             Tumors (RECIST) 1.1 for non-GBM tumors and by Response Assessment in Neuro-Oncology\n             (RANO) criteria for GBM\n\n          -  For stage 1 (all patients) and dose expansion (stage 2) endometrial and ovarian\n             cancer cohorts, participants are allowed following unlimited prior therapy; for stage\n             2 GBM participants, no more than 2 prior relapses are allowed; for these patients,\n             relapse is defined as progression following initial therapy (i.e. radiation +/- chemo\n             if that was used as initial therapy) or a subsequent therapy; the intent therefore is\n             that GBM patients enrolling onto stage 2 had no more than 3 prior therapies (initial\n             and treatment for 2 relapses); if the patient had a surgical resection for relapsed\n             disease and no anti-cancer therapy was instituted for up to 12 weeks, and the patient\n             undergoes another surgical resection, this is considered to constitute 1 relapse\n\n               -  NOTE: For participants who had prior therapy for a low-grade glioma, the\n                  surgical diagnosis of glioblastoma will be considered the first relapse;\n                  therefore, these participants may have had more than 3 prior therapies\n\n          -  Patients must have recovered from clinically significant toxicity of prior therapy to\n             grade =< 1 or pre-treatment baseline; the following intervals from previous\n             treatments are required prior to day 1 of study therapy:\n\n               -  12 weeks from the completion of radiation for recurrent GBM unless there is\n                  surgical diagnosis of recurrence or a new lesion that was not previously\n                  radiated\n\n               -  6 weeks from a nitrosourea chemotherapy\n\n               -  3 weeks from a non-nitrosourea chemotherapy\n\n               -  4 weeks from an investigational agent (not Food and Drug Administration [FDA]\n                  approved) (or 5 half lives, whichever is shorter)\n\n               -  2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,\n                  erlotinib, hydroxychloroquine, etc.) (or 5 half lives, whichever is shorter)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\n\n          -  Absolute neutrophil count >= 1,500/\u00b5L\n\n          -  Platelets >= 100,000/\u00b5L\n\n          -  Hemoglobin >= 9.0 g/dL\n\n          -  Total bilirubin < 1.5 x institutional upper limit of normal with direct bilirubin\n             within normal limits except for participants with Gilbert's disease\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 x institutional upper limit of normal (=< 5 x upper limit of normal [ULN] if\n             liver metastases are present)\n\n          -  Creatinine < 1.5 x normal institutional limits OR creatinine clearance >= 50\n             mL/min/1.73 m^2 for patients with creatinine level above institutional normal based\n             either on Cockroft-Gault estimate or based on urine collection (12 or 24 hour)\n\n          -  Metabolic: fasting serum glucose (=< 130 mg/dL) and fasting triglycerides =< 300\n             mg/dL\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry, the\n             duration of study participation and 6 months after completion of MLN 0128 or\n             bevacizumab administration; should a woman become pregnant or suspect she is pregnant\n             while she or her partner is participating in this study, she should inform her\n             treating physician immediately; men treated or enrolled on this protocol must also\n             agree to use adequate contraception prior to the study, for the duration of study\n             participation, and 6 months after completion of MLN0128 or bevacizumab administration\n\n          -  Patients must have no concurrent malignancy except curatively treated basal or\n             squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or\n             bladder; patients with prior malignancies must be disease-free for >= three years\n             prior to registration\n\n          -  Solid tumor patients must be off corticosteroids prior to registration; if GBM\n             patient is receiving corticosteroids, patient must be on a stable or decreasing dose\n             of corticosteroids for at least 5 days prior to baseline magnetic resonance imaging\n             (MRI) or computed tomography (CT); if steroids are added or the steroids dose is\n             increased between the date of the screening MRI or CT and the start of treatment, a\n             new baseline MRI or CT is required\n\n          -  Patients must be able to swallow whole capsules\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n          -  For stage 2 GBM participants, a block of paraffin embedded tissue or 30 unstained\n             slides at standard 4-5 um thickness from any prior surgery demonstrating GBM\n             pathology must be available for submission\n\n          -  Stage 2 endometrial and ovarian cancer patients must have at least one lesion\n             amenable to biopsy; this determination will be made by a member of the interventional\n             radiology team or surgical associate investigator and an associate investigator; this\n             requirement is not necessary for patients in stage 1\n\n          -  Solid tumor patients in stage 2 must have a diagnosis of papillary serous,\n             endometrioid or clear cell endometrial carcinoma or, high grade serous, clear cell,\n             endometrioid or mucinous ovarian, fallopian or primary peritoneal carcinoma\n\n        Exclusion Criteria:\n\n          -  Concurrent administration of any other investigational agents\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to MLN0128 or bevacizumab\n\n          -  For all stage 2 participants, no prior treatment with mTOR, PI3 kinase or Akt\n             inhibitors; prior treatment with mTOR, PI3 kinase or Akt inhibitors allowed in stage\n             1 only\n\n          -  For stage 2 GBM participants, no prior treatment with bevacizumab/vascular\n             endothelial growth factor receptor (VEGFR) inhibitors; prior treatment with\n             bevacizumab/VEGFR inhibitors is allowed in stage 1 for all participants, as well as\n             stage 2 endometrial and ovarian cancer participants\n\n          -  Stage 1 solid tumor and stage 2 endometrial and ovarian cancer participants with\n             known central nervous system (CNS) metastatic lesions which are symptomatic and/or\n             growing; patients previously treated for these conditions that are asymptomatic in\n             the absence of corticosteroid therapy are allowed to enroll; brain metastasis must be\n             stable for 1 month with verification by imaging (brain MRI completed at screening\n             demonstrating no current evidence of progressive brain metastases); CNS imaging will\n             not be mandated for asymptomatic patients with no history of CNS metastases\n\n          -  Concurrent use of enzyme-inducing anti-epileptic drugs (EIAED); patients may be on\n             non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs;\n             patients previously treated with EIAED may be enrolled if they have been off the\n             EIAED for 10 days or more prior to the first dose of MLN0128\n\n          -  Subjects taking strong cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2C19\n             (CYP2C19) inhibitors and/or inducers should be considered with caution; alternative\n             treatments that are less likely to affect MLN0128 metabolism, if available, should be\n             considered; if a subject requires treatment with 1 or more of the strong CYP3A4 and\n             CYP2C19 inhibitors and/or inducers, the principal investigator should be consulted\n\n          -  Concurrent use of herbal supplements and other non-traditional medications; all\n             herbal supplements and other non-traditional medications must be stopped before time\n             of registration\n\n          -  Concurrent use of anti-coagulants (warfarin, etc.) other than low-molecular weight\n             heparin (LMWH); medication must be stopped before time of registration; if patient\n             has recently been on anti-coagulants other than LMWH, patient must have INR =< 2\n\n          -  Evidence of any significant intracranial hemorrhage, as determined by the treating\n             investigator, within 6 weeks from registration or as seen on most recent MRI prior to\n             screening/baseline MRI\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements, are ineligible\n\n          -  History of any of the following within 6 months prior to start of MLN0128:\n\n          -  Left ventricular ejection fraction (LVEF) =< 55 % as determined by multi gated\n             acquisition (MUGA) scan or echocardiogram (ECHO)\n\n          -  Heart failure >= New York Heart Association (NYHA) grade 3\n\n          -  Significant ST depression of >= 1.5 mm in 2 or more leads and/or T wave inversions in\n             >= 2 leads\n\n          -  Complete left bundle branch block\n\n          -  Right bundle branch block + left anterior hemiblock (bi-fascicular block)\n\n          -  Congenital long QT syndrome\n\n          -  QT interval corrected by Fridericia's formula (QTcF) > 450 msec on screening\n             electrocardiogram (ECG)\n\n          -  Requirement of inotropic support (excluding digoxin)\n\n          -  History or presence of clinically significant ventricular or atrial tachyarrhythmias,\n             or cardiac arrest\n\n          -  Clinically significant resting bradycardia\n\n          -  Presence of unstable atrial fibrillation (ventricular response > 100 beats per\n             minute)\n\n          -  Patients with stable atrial fibrillation are allowed in the study provided they do\n             not meet the other cardiac exclusion criteria\n\n          -  History of arrhythmia requiring an implantable cardiac defibrillator\n\n          -  Angina pectoris =< 12 months prior to starting drug\n\n          -  Acute myocardial infarction =< 12 months prior to starting drug\n\n          -  Any valve disease Common Terminology Criteria for Adverse Events (CTCAE) grade\n\n          -  Ischemic myocardial event including angina requiring therapy and artery\n             revascularization procedures\n\n          -  Placement of a pacemaker for control of rhythm\n\n          -  Pulmonary embolism\n\n          -  Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery\n             revascularization procedures\n\n          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly\n             alter the absorption of oral MLN0128 (e.g., ulcerative diseases, uncontrolled nausea,\n             vomiting, diarrhea, malabsorption syndrome, small bowel resection that requires\n             nutritional support)\n\n          -  Use of hematopoietic colony-stimulating growth factors (e.g. filgrastim [G-CSF],\n             sargramostim [GMCSF], lanimostim [M-CSF]) =< 2 weeks prior to starting study drug;\n             erythropoietin, darbepoetin and erythropoietin-biosimilars are allowed for as long as\n             they have been initiated at least 2 weeks prior to study enrollment\n\n          -  Pregnant or nursing women; breastfeeding should be discontinued if the mother is\n             treated with MLN0128\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible; if an HIV-positive patient has adequate cluster of\n             differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and\n             is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP)\n             inhibitors, they will be eligible\n\n          -  Uncontrolled high blood pressure (i.e., systolic blood pressure >= 160 mmHg,\n             diastolic blood pressure >= 90 mmHg)\n\n          -  Pulmonary hypertension\n\n          -  Uncontrolled asthma or oxygen (O2) saturation < 90% by ABG (arterial blood gas)\n             analysis or pulse oximetry on room air\n\n          -  Participants with poorly controlled diabetes mellitus (defined as hemoglobin A1c\n             [HbA1c] > 7%); subjects with a history of transient glucose intolerance due to\n             corticosteroid administration are allowed in this study if all other\n             inclusion/exclusion criteria are met\n\n          -  Urine protein should be screened by urinalysis; if protein is 2+ or higher, 24 hour\n             urine protein should be obtained and the level should be < 1000 mg for patient\n             enrollment\n\n          -  Serious or non-healing wound, ulcer or bone fracture\n\n          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months prior to day 1\n\n          -  Invasive procedures defined as follows:\n\n               -  Major surgical procedure, open biopsy or significant traumatic injury within 28\n                  days prior to day 1 therapy\n\n               -  Anticipation of need for major surgical procedures during the course of the\n                  study\n\n               -  Core biopsy within 7 days prior to day 1 therapy\n\n          -  Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or\n             recent peripheral arterial thrombosis) within 6 months prior to day 1\n\n          -  Evidence of bleeding diathesis or coagulopathy\n\n          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other\n             recombinant human antibodies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142803", 
            "org_study_id": "NCI-2014-01118", 
            "secondary_id": [
                "NCI-2014-01118", 
                "14-079", 
                "9552", 
                "U01CA062490", 
                "P30CA006516", 
                "U01CA076576"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (MLN0128, bevacizumab)", 
                "description": "Given PO", 
                "intervention_name": "TORC1/2 inhibitor MLN0128", 
                "intervention_type": "Drug", 
                "other_name": [
                    "INK128", 
                    "MLN0128", 
                    "TORC1/2 Inhibitor INK128"
                ]
            }, 
            {
                "arm_group_label": "Treatment (MLN0128, bevacizumab)", 
                "description": "Given IV", 
                "intervention_name": "bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-VEGF humanized monoclonal antibody", 
                    "anti-VEGF monoclonal antibody", 
                    "Avastin", 
                    "rhuMAb VEGF"
                ]
            }, 
            {
                "arm_group_label": "Treatment (MLN0128, bevacizumab)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (MLN0128, bevacizumab)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Lakshmi_Nayak@DFCI.harvard.edu", 
                    "last_name": "Lakshmi Nayak", 
                    "phone": "617-632-2166"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Lakshmi Nayak", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chi.andrew@mgh.harvard.edu", 
                    "last_name": "Andrew S. Chi", 
                    "phone": "617-724-8770"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlestown", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02129"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Andrew S. Chi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lorussop@karmanos.org", 
                    "last_name": "Patricia M. LoRusso", 
                    "phone": "313-576-8716"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia M. LoRusso", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "john.hays@osumc.edu", 
                    "last_name": "John L. Hays", 
                    "phone": "614-685-5840"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "investigator": {
                    "last_name": "John L. Hays", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors", 
        "other_outcome": [
            {
                "description": "Plasma and CSF PK levels of MLN0128 obtained before and after bevacizumab administration will be evaluated and summarized. The ration of plasma to CSF PK levels will also be summarized.", 
                "measure": "CSF penetration of MLN0128, evaluated using plasma and CSF pharmacokinetic (PK) parameters of MLN0128", 
                "safety_issue": "No", 
                "time_frame": "2-3 hours post-dose day 15 of course 1 and day 1 of course 2"
            }, 
            {
                "description": "The biomarkers predicting response to mTOR inhibitor activity will be resulted by dose level and response status.", 
                "measure": "Markers associated with dysregulated cell signaling", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Change in phosphorylated proteins within tumor biopsies from patients with ovarian and endometrial cancers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to within 7 days after last study drug or within 7 days after decision to end treatment"
            }, 
            {
                "measure": "Change in circulating plasma levels of angiogenic growth factors in patients with ovarian and endometrial cancers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 1 of last course of treatment"
            }, 
            {
                "measure": "Mutation analysis of tissue from biopsies of patients with ovarian and endometrial cancers", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Lakshmi Nayak", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD/RP2D of MLN0128, determined according to incidence of dose-limiting toxicity, as graded using the National Cancer Institute (NCI) CTCAE version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Safety will be assessed through summaries of adverse events, changes in selected laboratory test results, changes in vital signs, and MLN0128 and bevacizumab exposure.", 
                "measure": "Incidence of adverse events, graded according to NCI CTCAE version 4.0", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Listed for all patients by dose level.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From date of first dose to date of progression or death, assessed at 6 months"
            }, 
            {
                "measure": "Objective RR, defined as a complete or partial response, as determined by investigator assessment using RECIST or RANO", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Listed for all patients by dose level.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Percentage will be summarized.", 
                "measure": "Frequency of toxicities leading to missed doses or delays", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "Percentage will be summarized.", 
                "measure": "Percentage of courses given or not within 7 days of their scheduled times", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "Percentage will be summarized.", 
                "measure": "Percentage of actual planned dosage administration", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "Percentage will be summarized.", 
                "measure": "Percentage of patients that discontinue study drugs due to treatment related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}